MUMBAI: If the stock market is any guide, Sharvil Patel has just inherited one of the top generic drug manufacturers in the world. Now, he just has to figure out how to keep it that way.
Even as the copycat drug business reeled from increased regulatory scrutiny, withering competition in the US, or some combination of the two, his family’s Cadila Healthcare Ltd seemed to have things worked out.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
